Aimei Health Technology II, the second blank check company formed by two China-based investors targeting small-cap health tech, filed on Monday with the SEC to raise up to $60 million in an initial public offering.
The company plans to raise $60 million by offering 6.0 million units at a price of $10. Each unit consists of one share of common stock and one right to receive one-seventh (1/7) of a share of common stock following a de-SPAC.
Aimei Health Technology II lists its headquarters as New York, NY, but notes that its sponsor is based in mainland China, while its CEO is based in Hong Kong.
The SPAC is led by CEO, CFO, and Director Heung Ming Wong, who also serves as CFO of Aimei Health Technology (AFJK), a SPAC that raised $60 million in December 2023, and has a pending merger agreement with China-based hydrogen producer United Hydrogen Global. Mr. Heung Ming Wong also serves on the boards of several publicly-traded companies, and previously served as CFO of Meten EdtechX Education Group.
The SPAC plans to pursue small cap companies based in North America, Europe, or Asia Pacific (including China) that are focused on healthcare innovation, including biopharmaceutical, medical technology/medical device, and diagnostics companies.
Aimei Health Technology II was founded in 2024. It plans to list its units on the Nasdaq under the symbol AHJKU. A.G.P. is the sole bookrunner on the deal. No pricing date has been determined.
